Integrin α v β 3  receptor targeting PET/MRI dual-modal imaging probe based on the  64 Cu labeled manganese ferrite nanoparticles

Shi, Xudong; Shen, Langtao

doi:10.1016/j.jinorgbio.2018.06.004

Cited by 17 publications

(14 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, various studies now confirm the diagnostic potential and advantages of PET imaging for GBM patients due to better tumor delineation or monitoring tumor progression [18,19]. Recently, radiolabeled RGD peptides were successfully used to image other human carcinomas with PET technology [20] and RGD-sequence peptides remain emerging candidates for glioblastoma imaging [21,22,23].…”

Section: Discussionmentioning

confidence: 99%

Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme

et al. 2019

View full text Add to dashboard Cite

In this study, we have compared four 68Ga-labeled peptides (three Arg-Gly-Asp (RGD) peptides and substance-P) with two 18F-tracers clinically approved for tumor imaging. We have studied in vitro and in vivo characteristics of selected radiolabeled tracers in a glioblastoma multiforme tumor model. The in vitro part of the study was mainly focused on the evaluation of radiotracers stability under various conditions. We have also determined in vivo stability of studied 68Ga-radiotracers by analysis of murine urine collected at various time points after injection. The in vivo behavior of tested 68Ga-peptides was evaluated through ex vivo biodistribution studies and PET/CT imaging. The obtained data were compared with clinically used 18F-tracers. 68Ga-RGD peptides showed better imaging properties compared to 18F-tracers, i.e., higher tumor/background ratios and no accumulation in non-target organs except for excretory organs.

show abstract

Section: Discussionmentioning

confidence: 99%

Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The preparation of a nanostructure, surface functionalization, and the attachment of a targeting molecule are often long and multi-stage processes. 34 , 38–40 , 49 , 50 , 53 , 57 , 59 , 60 , 62 More reaction steps require more time from the operator and might affect the reproducibility; therefore, modular and one-pot syntheses are gaining in popularity due to faster tracer preparation times and often lower costs. Moon et al reported shorter one-/two-step encapsulation methods for the synthesis of iron oxide with DOTA-SA and GUL-SA moieties.…”

Section: Real Problemsmentioning

confidence: 99%

Targeted PET/MRI Imaging Super Probes: A Critical Review of Opportunities and Challenges

Kastelik-Hryniewiecka¹,

Jewuła²,

Bakalorz³

et al. 2022

IJN

View full text Add to dashboard Cite

Recently, the demand for hybrid PET/MRI imaging techniques has increased significantly, which has sparked the investigation into new ways to simultaneously track multiple molecular targets and improve the localization and expression of biochemical markers. Multimodal imaging probes have recently emerged as powerful tools for improving the detection sensitivity and accuracy—both important factors in disease diagnosis and treatment; however, only a limited number of bimodal probes have been investigated in preclinical models. Herein, we briefly describe the strengths and limitations of PET and MRI modalities and highlight the need for the development of multimodal molecularly-targeted agents. We have tried to thoroughly summarize data on bimodal probes available on PubMed. Emphasis was placed on their design, safety profiles, pharmacokinetics, and clearance properties. The challenges in PET/MR probe development using a number of illustrative examples are also discussed, along with future research directions for these novel conjugates.

show abstract

“…Based on the experience in the field of artificial siderophores and chelating agents, and the increasing interest in metal-based radiopharmaceuticals [52][53][54][55][56][57][58], in 2010 Shen et al developed a 3,4-HOPO based ligand, cyclen-3,4-HOPO. In this ligand, a cyclen was used as a tripodal scaffold [59,60].…”

Section: Multidentate Hydroxypyridinonesmentioning

confidence: 99%

“…Through 1:1 coordination, the stable metal complexes formed by NTP(PrHP) 3 account for only 82%. In addition, since the fulcrum of the tripodal chelator is a nitrogen atom of a tertiary amine, it cannot be used as a bifunctional ligand for the coupling of targeted molecules[51].Based on the experience in the field of artificial siderophores and chelating agents, and the increasing interest in metal-based radiopharmaceuticals[52][53][54][55][56][57][58], in 2010 Shen et al developed a 3,4-HOPO based ligand, cyclen-3,4-HOPO. In this ligand, a cyclen was used as…”

mentioning

confidence: 99%

Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals

Zhou¹,

Dong²,

Shen

2021

Molecules

Self Cite

View full text Add to dashboard Cite

Hydroxypyridinones (HOPOs) have been used in the chelation therapy of iron and actinide metals. Their application in metal-based radiopharmaceuticals has also been increasing in recent years. This review article focuses on how multidentate HOPOs can be used in targeted radiometal-based diagnostic and therapeutic radiopharmaceuticals. The general structure of radiometal-based targeted radiopharmaceuticals, a brief description of siderophores, the basic structure and properties of bidentate HOPO, some representative HOPO multidentate chelating agents, radiopharmaceuticals based on HOPO multidentate bifunctional chelators for gallium-68, thorium-227 and zirconium-89, as well as the future prospects of HOPO multidentate bifunctional chelators in other metal-based radiopharmaceuticals are described and discussed in turn. The HOPO metal-based radiopharmaceuticals that have shown good prospects in clinical and preclinical studies are gallium-68, thorium-227 and zirconium-89 radiopharmaceuticals. We expect HOPO multidentate bifunctional chelators to be a very promising platform for building novel targeted radiometal-based diagnostic and therapeutic radiopharmaceuticals.

show abstract

Integrin α v β 3 receptor targeting PET/MRI dual-modal imaging probe based on the 64 Cu labeled manganese ferrite nanoparticles

Cited by 17 publications

References 21 publications

Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme

Preclinical Evaluation of Radiolabeled Peptides for PET Imaging of Glioblastoma Multiforme

Targeted PET/MRI Imaging Super Probes: A Critical Review of Opportunities and Challenges

Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals

Contact Info

Product

Resources

About